# US 2021/0261533 A1 · 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261533 A1
- Document ID: US20210261533A1
- Status: Published application
- Kind: A1
- Application number: 17/315,791
- Filed: 2021-05-10
- Published: 2021-08-26
- Earliest claimed: 2007-05-08
- Assignees: Bial - Portela & Ca, S.A.
- Applicants: Bial - Portela & Ca, S.A.
- Inventors: Patrício Manuel V.A. Soares Da Silva; David Alexander Learmonth; Alexander Beliaev
- Web page: https://patentgrep.com/patent/US20210261533A1

## CPC

- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/22: Anxiolytics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula I and a method for their preparation are described, where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies -alkyl-aryl or alkyl heteroaryl; X signifies CH2, oxygen atom or sulphur atom; n is 2 or 3; including the individual (R)- and (S)-enantiomers or mixtures of enantiomers thereof; and including pharmaceutically acceptable salts and esters thereof. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.

## Claims

### Claim 1

A compound of formula I:
where R1, R2 and R3 are the same or different and signify hydrogen, halogen, alkyl, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies -alkyl-aryl or -alkyl-heteroaryl; X signifies CH2, oxygen atom or sulphur atom; n is 2 or 3; the individual (R)- and (S)-enantiomers or mixtures of enantiomers thereof; or pharmaceutically acceptable salts or esters thereof, wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means a phenyl or naphthyl group, optionally substituted by alkyl, alkyloxy, halogen or nitro group; the term halogen means fluorine, chlorine, bromine or iodine; the term heteroaryl means heteroaromatic group.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein n is 2.

### Claim 3 (depends on 1, 2)

A compound according to claim 1 or 2, wherein X is O.

### Claim 4

A compound according to any preceding claim, wherein R4 signifies —CH2-aryl or —CH2— heteroaryl.

### Claim 5

A compound according to any preceding claim, wherein the aryl group of R4 is unsubstituted.

### Claim 6

A compound according to any preceding claim, wherein the aryl group of R4 is phenyl.

### Claim 7

A compound according to any preceding claim, wherein one of R1, R2 and R3 is hydrogen, and the others are fluorine.

### Claim 8

A compound according to any preceding claim, wherein said compound consists of the R-enantiomer.

### Claim 9

A compound according to any preceding claim, comprising the hydrochloride salt of the compound of formula I.

### Claim 10 (depends on 1)

A process for the preparation of the individual (R)- and (S)-enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts or esters of a compound of formula I, which comprises reacting the individual (R)- or (S)-enantiomers or mixtures of enantiomers of a compound of Formula III
where X, R1, R2, R3 and n have the same meaning as in claim 1, with a compound of formula IV
where R5 signifies aryl or heteroaryl, wherein the term aryl means a phenyl or naphthyl group, optionally substituted by alkyl, alkyloxy, halogen or nitro group; the term halogen means fluorine, chlorine, bromine or iodine; the term heteroaryl means heteroaromatic group; under reductive alkylation conditions.

### Claim 11

A compound of formula X:
its (R) or (S) enantiomer, or mixture of (R) and (S) enantiomer, or pharmaceutically acceptable salts or esters thereof.

### Claim 12 (depends on 11)

A compound according to claim 11, wherein the compound is the (R) enantiomer of the compound of Formula X.

### Claim 13 (depends on 11, 12)

A compound according to claim 11 or 12, comprising the hydrochloride salt of the compound of formula X.

### Claim 14 (depends on 11, 12, 13)

A process for the preparation of the compound of formula X of any of claims 11 to 13, which comprises treatment of (R)-5-(2-aminoethyl)-1-(6,8-difluoro-chroman-3-yl)-1,3-dihydroimidazole-2-thione and benzaldehyde under reductive alkylation reaction conditions.

### Claim 15 (depends on 14)

The process according to claim 14 wherein the reductive alkylation is performed in the presence of a reducing reagent.

### Claim 16 (depends on 15)

A process according to claim 15 wherein the reducing reagent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, or hydrogen in the presence of a hydrogenation catalyst.

### Claim 17 (depends on 14, 15, 16)

The process according to any of claims 14 to 16 wherein the treatment takes place in a mixture of methanol and dichloromethane.

### Claim 18 (depends on 14, 15, 16, 17)

The process according to any of claims 14 to 17 wherein the process further includes a purification step.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 in combination with a pharmaceutically effective carrier.

### Claim 20 (depends on 19)

A pharmaceutical composition according to claim 19 further comprising a compound selected from one or more of the following classes of compounds:
diuretics; beta-adrenergic antagonists; alpha2-adrenergic agonists; alpha1-adrenergic antagonists; dual beta- and alpha-adrenergic antagonists; calcium channel blockers; potassium channel activators; anti-arrhythmics; ACE inhibitors; AT1 receptor antagonists; renin inhibitors; lipid lowerers, vasopeptidase inhibitors; nitrates; endothelin antagonists; neutral endopeptidase inhibitors; anti-angiotensin vaccines; vasodilators; phosphodiesterase inhibitors; cardiac glycosides; serotonin antagonists; CNS acting agents; calcium sensitisers; HMG CoA reductase inhibitors; vasopressin antagonists; adenosine A1 receptor antagonists; atrial natriuretic peptide (ANP) agonists; chelating agents; corticotrophin-releasing factor receptor; glucagon-like peptide-1 agonists; sodium, potassium ATPase inhibitors; advanced glycosylation end-products (AGE) crosslink breakers; mixed neprilysin/endotheliin-converting enzyme (NEP/ECE) inhibitors; nociceptin receptor (ORL-1) agonists; xanthine oxidase inhibitors; benzodiazepine agonists; cardiac myosin activators; chymase inhibitors; endothelial nitric oxide synthase (ENOS) transcription enhancers; and neutral endopeptidase inhibitors.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A compound according to any one of claims 1 to 9, 11 to 13, for use as a medicament.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according to any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for treating disorders where a reduction in the hydroxylation of dopamine to noradrenaline is of therapeutic benefit.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for treating a subject afflicted by anxiety disorders.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for treating migraine.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for treating a subject afflicted by cardiovascular disorders.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for treating hypertension, or chronic or congestive heart failure.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for treating one or more of the following indications: angina, arrhythmias, and circulatory disorders such as Raynaud's phenomenon.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

The use of a compound according any one of claims 1 to 9, 11 to 13, in the manufacture of a medicament for use in inhibiting dopamine-β-hydroxylase.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A method of treating anxiety disorders comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 to a patient in need thereof.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A method of treating migraine comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 to a patient in need thereof.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A method of treating cardiovascular disorders comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 to a patient in need thereof.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A method of treating hypertension comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 to a patient in need thereof.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A method of treating chronic or congestive heart failure comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 to a patient in need thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13)

A method of treating one or more of the following indications: angina, arrhythmias, and circulatory disorders such as Raynaud's phenomenon comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 9, 11 to 13 to a patient in need thereof.

### Claim 35 (depends on 29, 30, 31, 32, 33, 34)

A method according to any one of claims 29 to 34 further comprising the administration of a compound selected from one or more of the following classes of compounds:
diuretics; beta-adrenergic antagonists; alpha2-adrenergic agonists; alpha1-adrenergic antagonists; dual beta- and alpha-adrenergic antagonists; calcium channel blockers; potassium channel activators; anti-arrhythmics; ACE inhibitors; AT1 receptor antagonists; renin inhibitors; lipid lowerers, vasopeptidase inhibitors; nitrates; endothelin antagonists; neutral endopeptidase inhibitors; anti-angiotensin vaccines; vasodilators; phosphodiesterase inhibitors; cardiac glycosides; serotonin antagonists; CNS acting agents; calcium sensitisers; HMG CoA reductase inhibitors; vasopressin antagonists; adenosine A1 receptor antagonists; atrial natriuretic peptide (ANP) agonists; chelating agents; corticotrophin-releasing factor receptor; glucagon-like peptide-1 agonists; sodium, potassium ATPase inhibitors; advanced glycosylation end-products (AGE) crosslink breakers; mixed neprilysin/endotheliin-converting enzyme (NEP/ECE) inhibitors; nociceptin receptor (ORL-1) agonists; xanthine oxidase inhibitors; benzodiazepine agonists; cardiac myosin activators; chymase inhibitors; endothelial nitric oxide synthase (ENOS) transcription enhancers; and neutral endopeptidase inhibitors.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 35)

A method according to claim 35 wherein the administration of the compound(s) selected from the listed classes of compounds is simultaneous to the administration of the compound according to any one of claims 1 to 9, 11 to 13.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 35)

A method according to claim 35 wherein the administration of the compound(s) selected from the listed classes of compounds is sequential to the administration of the compound according to any one of claims 1 to 9, 11 to 13.
